GXMC
ABUS icon

Global X Management Company’s Arbutus Biopharma ABUS Stock Holding History

Global X Management Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,134
Closed -$31K – 881
2015
Q3 		$31K Buy
+5,134
New +$45.5K ﹤0.01% 420

Other funds holding ABUS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Global X Management Company's ABUS Position: Q4 2015 in Review

Global X Management Company sold out of Arbutus Biopharma (ABUS) in Q4 2015, closing a stake of 5,134 shares — an estimated $31K sold.

Global X Management Company first reported a position in ABUS in Q3 2015 and held it in 1 quarter. The position peaked at $31K in Q3 2015. 51 funds tracked by Wall St. Rank hold ABUS as of Q4 2015.

  • Global X Management Company reported no remaining Arbutus Biopharma position as of Q4 2015 after selling out during the quarter.
  • Global X Management Company sold 5,134 Arbutus Biopharma shares in Q4 2015, an estimated $31K.
  • Global X Management Company first reported a position in Arbutus Biopharma in Q3 2015 and held it in 1 quarter.
  • Global X Management Company's Arbutus Biopharma position peaked at $31K in Q3 2015.
  • 51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2015.

Based on Global X Management Company's 13F filing for Q4 2015, filed 11 Feb 2016.